KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Other Accumulated Expenses: 2013-2025

Historic Other Accumulated Expenses for Novavax (NVAX) over the last 11 years, with Sep 2025 value amounting to $138.3 million.

  • Novavax's Other Accumulated Expenses fell 50.90% to $138.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $138.3 million, marking a year-over-year decrease of 50.90%. This contributed to the annual value of $219.6 million for FY2024, which is 74.51% down from last year.
  • As of Q3 2025, Novavax's Other Accumulated Expenses stood at $138.3 million, which was up 4.38% from $132.5 million recorded in Q2 2025.
  • Over the past 5 years, Novavax's Other Accumulated Expenses peaked at $930.1 million during Q4 2022, and registered a low of $2.4 million during Q1 2021.
  • In the last 3 years, Novavax's Other Accumulated Expenses had a median value of $242.8 million in 2024 and averaged $430.0 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first spiked by 4,312.95% in 2022, then slumped by 74.51% in 2024.
  • Novavax's Other Accumulated Expenses (Quarterly) stood at $36.1 million in 2021, then surged by 2,479.12% to $930.1 million in 2022, then decreased by 7.38% to $861.4 million in 2023, then crashed by 74.51% to $219.6 million in 2024, then slumped by 50.90% to $138.3 million in 2025.
  • Its Other Accumulated Expenses was $138.3 million in Q3 2025, compared to $132.5 million in Q2 2025 and $142.0 million in Q1 2025.